Literature DB >> 29766268

Electrocardiographic and echocardiographic findings in muscular dystrophy patients with heart failure.

Masataka Ogiso1, Toshiaki Isogai2, Ken Kato2, Hiroyuki Tanaka2, Tamotsu Tejima2, Eiji Isozaki3.   

Abstract

Cardiac involvement in muscular dystrophy (MD) is known to cause heart failure (HF). However, little is known about the differences in electrocardiographic and echocardiographic findings between MD patients with and without the experience of hospitalization for HF. We retrospectively identified 95 MD patients (mean age at diagnosis of MD 41.1 ± 18.7 years; males 64.2%), including nine (9.4%) patients who were hospitalized for HF (the HF group) and 86 (90.6%) patients who were not (the non-HF group) during the follow-up period (16.7 ± 12.2 years). The HF group had a significantly wider QRS duration (126.0 ± 37.6 vs. 98.1 ± 16.7 ms, p < 0.001) and QTc interval (454.6 ± 50.5 vs. 409.5 ± 23.6 ms, p < 0.001) at the time of HF hospitalization than the non-HF group. The HF group also had a significantly lower left ventricular (LV) ejection fraction (35.4 ± 19.2 vs. 62.5 ± 11.3%, p < 0.001) and significantly larger diastolic LV dimension (64 ± 2 vs. 45 ± 1 mm, p < 0.001) and left atrial diameter (38 ± 12 vs. 29 ± 6 mm, p = 0.003) at the time of HF hospitalization than the non-HF group. In the HF group, the QRS duration was significantly wider at the time of HF hospitalization than at the initial electrocardiogram before the development of HF (129.8 ± 30.7 vs. 119.0 ± 33.3 ms, p = 0.018). This study suggests that HF occurs in MD patients with electrocardiographic and echocardiographic abnormalities. Early recognition of abnormal findings during a regular electrocardiographic or echocardiographic follow-up may be useful for identifying cardiac involvement in MD.

Entities:  

Keywords:  Echocardiography; Electrocardiography; Heart failure; Muscular dystrophy

Mesh:

Year:  2018        PMID: 29766268     DOI: 10.1007/s00380-018-1186-5

Source DB:  PubMed          Journal:  Heart Vessels        ISSN: 0910-8327            Impact factor:   2.037


  30 in total

1.  Echocardiographic clues to diagnosis of dystrophin related dilated cardiomyopathy.

Authors:  C Rapezzi; O Leone; E Biagini; F Coccolo
Journal:  Heart       Date:  2007-01       Impact factor: 5.994

2.  Guidelines for treatment of acute heart failure (JCS 2011).

Authors: 
Journal:  Circ J       Date:  2013-06-12       Impact factor: 2.993

3.  [A longitudinal cause-of-death analysis of patients with Duchenne muscular dystrophy].

Authors:  Tsuyoshi Matsumura; Toshio Saito; Harutoshi Fujimura; Susumu Shinno; Saburo Sakoda
Journal:  Rinsho Shinkeigaku       Date:  2011-10

Review 4.  Cardiomyopathy of Duchenne muscular dystrophy: current understanding and future directions.

Authors:  Christopher F Spurney
Journal:  Muscle Nerve       Date:  2011-07       Impact factor: 3.217

Review 5.  Definition and epidemiology of acute heart failure syndromes.

Authors:  Markku S Nieminen; Veli-Pekka Harjola
Journal:  Am J Cardiol       Date:  2005-09-19       Impact factor: 2.778

6.  Cardiac manifestations and their management in Becker's muscular dystrophy.

Authors:  Y S Orlov; M A Brodsky; B J Allen; R A Ott; M V Orlov; C A Jay
Journal:  Am Heart J       Date:  1994-07       Impact factor: 4.749

Review 7.  The muscular dystrophies.

Authors:  Alan E H Emery
Journal:  Lancet       Date:  2002-02-23       Impact factor: 79.321

8.  Prognostic factors in mild dystrophinopathies.

Authors:  C Angelini; M Fanin; M P Freda; F Martinello; M Miorin; P Melacini; G Siciliano; E Pegoraro; M Rosa; G A Danieli
Journal:  J Neurol Sci       Date:  1996-10       Impact factor: 3.181

9.  Association of QRS duration with left ventricular structure and function and risk of heart failure in middle-aged and older adults: the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Leonard Ilkhanoff; Kiang Liu; Hongyan Ning; Saman Nazarian; David A Bluemke; Elsayed Z Soliman; Donald M Lloyd-Jones
Journal:  Eur J Heart Fail       Date:  2012-07-12       Impact factor: 15.534

10.  Beneficial effects of beta-blockers and angiotensin-converting enzyme inhibitors in Duchenne muscular dystrophy.

Authors:  Hitoko Ogata; Yuka Ishikawa; Yukitoshi Ishikawa; Ryoji Minami
Journal:  J Cardiol       Date:  2008-10-23       Impact factor: 3.159

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.